Informed design
Re-engineering of known, human peptide activators
Novel Targets
Effective exploitation of previously untapped receptors
Beta-cell health
Improving pancreatic beta-cell health to halt disease progression
About Us
Driving innovation in metabolic disease
Dia Beta Labs is a UK-based biotech company building on over 30 years of translational research from our founding research group at Ulster University, Northern Ireland.
We are committed to transforming the lives of metabolic disease sufferers through the development of our novel therapeutic pipeline.
We are developing agents which seek to address the progressive decline of pancreatic health in sufferers whilst imparting more sustainable, quality weight loss than currently available options.
The Problem
The uncurbed prevalence of diabetes and obesity is one of the greatest global healthcare challenges of our time. Over 2 billion adults are estimated to be overweight globally, the primary environmental driver for development of Type 2 Diabetes.
537 million adults are living with diabetes worldwide
This is predicted to reach 642 million by 2040
90% of global cases are Type 2 diabetic
2 billion people globally are either overweight or obese
The global economic cost of diabetes was estimated to be approximately $966 billion in 2021
Over 80% of this was attributed to management of avoidable, life-altering diabetic complications
Diabetic complications:
- Vision loss
- Amputation
- Heart attack
- Stroke
- Kidney problems
- Nerve damage
- Gum disease
There exists a clear need for novel medicines which:
- Better manage disease progression
- Prevent development of complications
Our Solution
Our therapeutic candidates act at target receptors on the surface of insulin-producing beta-cells to:
Rest Beta-cells
Prevent further burnout of dwindling beta-cell mass
Improve function
Increase releasable insulin stores and overall sensitivity
Increase cell mass
Promote beta-cell proliferation, reduce apoptosis and improve beta-cell identity
Prevent Decline
Put a stopper in and actively reverse progressive beta-cell decline in severe disease
Our Therapeutic Candidates
Dia Beta Labs are currently progressing three therapeutic peptides through preclinical development for treatment of metabolic diseases in tandem
peptide analogues
Based on re-design of the human hormone receptor activators
Enzyme resistant
Improved stability against enzymatic degradation in plasma
Receptor selectivity
Improved selectivity towards target receptors of interest
Excellent Solubility
Enabling easier formulation compared to many peptides
